PDS Biotechnology (NASDAQ:PDSB) Raised to “Hold” at Wall Street Zen

PDS Biotechnology (NASDAQ:PDSB) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PDS Biotechnology in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, PDS Biotechnology has a consensus rating of “Hold” and an average price target of $9.00.

PDS Biotechnology Price Performance

PDS Biotechnology stock opened at $0.64 on Friday. The company has a market capitalization of $35.45 million, a P/E ratio of -0.85 and a beta of 1.20. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.09 and a current ratio of 2.09. PDS Biotechnology has a fifty-two week low of $0.51 and a fifty-two week high of $1.92. The stock has a 50-day simple moving average of $0.68 and a 200-day simple moving average of $0.84.

PDS Biotechnology (NASDAQ:PDSB) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.06. Equities research analysts expect that PDS Biotechnology will post -1.2 earnings per share for the current year.

Hedge Funds Weigh In On PDS Biotechnology

Institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP purchased a new stake in PDS Biotechnology during the 2nd quarter valued at approximately $91,000. Jane Street Group LLC purchased a new position in shares of PDS Biotechnology in the 2nd quarter valued at approximately $92,000. Watts Gwilliam & Co. LLC acquired a new position in shares of PDS Biotechnology in the second quarter valued at approximately $73,000. Inspirion Wealth Advisors LLC increased its holdings in shares of PDS Biotechnology by 338.5% in the third quarter. Inspirion Wealth Advisors LLC now owns 344,394 shares of the company’s stock valued at $348,000 after purchasing an additional 265,862 shares during the period. Finally, Squarepoint Ops LLC raised its stake in shares of PDS Biotechnology by 116.1% during the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock worth $295,000 after purchasing an additional 156,662 shares during the last quarter. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.